Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23
- PMID: 33616712
- DOI: 10.1007/s00223-021-00823-6
Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23
Abstract
Osteocyte produced fibroblast growth factor 23 (FGF23) is the key regulator of serum phosphate (Pi) homeostasis. The interplay between parathyroid hormone (PTH), FGF23 and other proteins that regulate FGF23 production and serum Pi levels is complex and incompletely characterised. Evidence suggests that the protein product of the SOST gene, sclerostin (SCL), also a PTH target and also produced by osteocytes, plays a role in FGF23 expression, however the mechanism for this effect is unclear. Part of the problem of understanding the interplay of these mediators is the complex multi-organ system that achieves Pi homeostasis in vivo. In the current study, we sought to address this using a cell line model of the osteocyte, IDG-SW3, known to express FGF23 at both the mRNA and protein levels. In cultures of differentiated IDG-SW3 cells, both PTH1-34 and recombinant human (rh) SCL remarkably induced Fgf23 mRNA expression dose-dependently within 3 h. Both rhPTH1-34 and rhSCL also strongly induced C-terminal FGF23 protein secretion. Secreted intact FGF23 levels remained unchanged, consistent with constitutive post-translational cleavage of FGF23 in this cell model. Both rhPTH1-34 and rhSCL treatments significantly suppressed mRNA levels of Phex, Dmp1 and Enpp1 mRNA, encoding putative negative regulators of FGF23 levels, and induced Galnt3 mRNA expression, encoding N-acetylgalactosaminyl-transferase 3 (GalNAc-T3), which protects FGF23 from furin-like proprotein convertase-mediated cleavage. The effect of both rhPTH1-34 and rhSCL was antagonised by pre-treatment with the NF-κβ signalling inhibitors, BAY11 and TPCK. RhSCL also stimulated FGF23 mRNA expression in ex vivo cultures of human bone. These findings provide evidence for the direct regulation of FGF23 expression by sclerostin. Locally expressed sclerostin via the induction of FGF23 in osteocytes thus has the potential to contribute to the regulation of Pi homeostasis.
Keywords: FGF23; IDG-SW3; PTH; Phosphate homeostasis; SOST; Sclerostin.
Similar articles
-
Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli.Mol Cell Endocrinol. 2015 Jan 5;399:208-18. doi: 10.1016/j.mce.2014.10.007. Epub 2014 Oct 16. Mol Cell Endocrinol. 2015. PMID: 25458698
-
Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.Bone. 2011 Oct;49(4):636-43. doi: 10.1016/j.bone.2011.06.025. Epub 2011 Jun 25. Bone. 2011. PMID: 21726676 Free PMC article.
-
Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo.J Bone Miner Res. 2011 Nov;26(11):2634-46. doi: 10.1002/jbmr.465. J Bone Miner Res. 2011. PMID: 21735478 Free PMC article.
-
Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23.Biofactors. 2014 Nov-Dec;40(6):555-68. doi: 10.1002/biof.1186. Epub 2014 Oct 29. Biofactors. 2014. PMID: 25352227 Review.
-
Roles of osteocytes in phosphate metabolism.Front Endocrinol (Lausanne). 2022 Jul 15;13:967774. doi: 10.3389/fendo.2022.967774. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909535 Free PMC article. Review.
Cited by
-
Osteocytes and the pathogenesis of hypophosphatemic rickets.Front Endocrinol (Lausanne). 2022 Sep 29;13:1005189. doi: 10.3389/fendo.2022.1005189. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246908 Free PMC article. Review.
-
Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia.Bone Rep. 2023 Feb 2;18:101659. doi: 10.1016/j.bonr.2023.101659. eCollection 2023 Jun. Bone Rep. 2023. PMID: 36817167 Free PMC article.
-
Indoxyl sulfate induces left ventricular hypertrophy via the AhR-FGF23-FGFR4 signaling pathway.Front Cardiovasc Med. 2023 Feb 21;10:990422. doi: 10.3389/fcvm.2023.990422. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36895836 Free PMC article.
-
New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease-Mineral and Bone Disorder.Metabolites. 2021 Dec 7;11(12):849. doi: 10.3390/metabo11120849. Metabolites. 2021. PMID: 34940607 Free PMC article. Review.
-
Emerging concepts on the FGF23 regulation and activity.Mol Cell Biochem. 2025 Jan;480(1):75-89. doi: 10.1007/s11010-024-04982-6. Epub 2024 Apr 6. Mol Cell Biochem. 2025. PMID: 38581553 Review.
References
-
- ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348
-
- Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774 - PubMed
-
- Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123 - PubMed
-
- Ito N, Findlay DM, Atkins GJ (2014) Osteocyte communication with the kidney via the production of FGF23: remote control of phosphate homeostasis. Clin Rev Bone Miner Metab 12:44–58
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous